FDA tentatively approves a generic for CML wonder-drug Gleevec
The US FDA has given tentative approval to India's Sun Pharmaceutical Industries for an abbreviated new drug application for generic Gleevec (imatinib mesilate) tablets. When Gleevec was introduced in 2001 for the treatment of chronic myleoid leukemia (CML), it was hailed as nothing short of a miracle drug and a magic bullet, and eight years later the medication has lost none of that shine.
However, despite being one of cancer's most remarkable success stories, the Swiss manufacturer Novarits has held tightly to the patent, and a full regimen of the medication costs an astonishing $32,000.
The FDA's tentative approval, coupled with India's unique patent laws, mean that a much more affordable generic version of the medication could be made available in the US some time next year.
Sources:
Therapeutics Daily
Medecins Sans Frontieres
thaindian.com
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
